GATA3, HDAC6, and BCL6 Regulate FOXP3+ Treg Plasticity and Determine Treg Conversion into Either Novel Antigen-Presenting Cell-Like Treg or Th1-Treg

Keman Xu1,2†, William Y. Yang1,2†, Gayani Kanchana Nanayakkara1,2, Ying Shao1,2, Fan Yang1, Wenhui Hu1,3, Eric T. Choi1,4, Hong Wang1,5 and Xiaofeng Yang1,2,5*

1 Center for Metabolic Disease Research, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States, 2 Center for Cardiovascular Research & Thrombosis Research, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States, 3 Department of Pathology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States, 4 Department of Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States, 5 Department of Pharmacology, Microbiology and Immunology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States

We conducted an experimental database analysis to determine the expression of 61 CD4+ Th subset regulators in human and murine tissues, cells, and in T-regulatory cells (Treg) in physiological and pathological conditions. We made the following significant findings: (1) adipose tissues of diabetic patients with insulin resistance upregulated various Th effector subset regulators; (2) in skin biopsy from patients with psoriasis, and in blood cells from patients with lupus, effector Th subset regulators were more upregulated than downregulated; (3) in rosiglitazone induced failing hearts in ApoE-deficient (KO) mice, various Th subset regulators were upregulated rather than downregulated; (4) aortic endothelial cells activated by proatherogenic stimuli secrete several Th subset-promoting cytokines; (5) in Treg from follicular Th (Tfh)-transcription factor (TF) Bcl6 KO mice, various Th subset regulators were upregulated; whereas in Treg from Th2-TF GATA3 KO mice and HDAC6 KO mice, various Th subset regulators were downregulated, suggesting that Bcl6 inhibits, GATA3 and HDAC6 promote, Treg plasticity; and (6) GATA3 KO, and Bcl6 KO Treg upregulated MHC II molecules and T cell co-stimulation receptors, suggesting that GATA3 and BCL6 inhibit Treg from becoming novel APC-Treg. Our data implies that while HDAC6 and Bcl6 are important regulators of Treg plasticity, GATA3 determine the fate of plastic Treg by controlling whether it will convert in to either Th1-Treg or APC-Treg. Our results have provided novel insights on Treg plasticity into APC-Treg and Th1-Treg, and new therapeutic targets in metabolic diseases, autoimmune diseases, and inflammatory disorders.

Keywords: CD4+ Th helper subset differentiation, CD4+ FOXP3+ regulatory T cells, metabolic cardiovascular diseases, Th1-like Treg, APC-like Treg

INTRODUCTION

CD4+ FOXP3+ (forkhead box P3) regulatory T cells (Treg) are classified as a subset of CD4+ T cells (T helper cells—Th), and they are specialized in suppression of immunopathological reactions in host immune system against antigens and dangers (1). In addition to inhibition of adaptive immune response, Treg also play a critical role in controlling various innate immune responses involved
in cancers (2), inflammatory diseases including cardiovascular diseases and atherosclerosis (3). Also, Treg facilitate blood flow recovery after ischemia (4), control adipose tissue inflammation, and promote muscle repair (5). Treg’s role in maintaining self-tolerance and prevention of autoimmune responses and chronic inflammation is mediated by various mechanisms such as (a) Treg killing of target cells (2); (b) modulation of target cells via cell–cell contact; (c) secretion of anti-inflammatory/immunosuppressive cytokines (6) including interleukin-10 (IL-10), IL-35 (7–9), and transforming growth factor-β (TGF-β); as well as (d) inhibition of target cells by exosome-carried microRNAs (1). We previously reported that Treg cell death pathways (1, 10–18), Treg generated IL-35 (7–9), and epigenetic pathways (19, 20) may be novel therapeutic targets for maintaining Treg survival, preventing Treg from becoming pathological Treg (1), and suppressing vascular inflammation (3).

Current understanding on Th differentiation is that in response to stimulation by several different inducing cytokines such as interferon-γ (IFN-γ), IL-12, and IL-4, and also depending on the anatomical location (21), naïve CD4+ T cells can be differentiated/polarized into at least nine terminally differentiated Th cell subsets. These subsets include Th helper cell 1 (Th1), Th2, Th9, follicular T (Tfh) (21), Th17, Treg, Th22 (1, 22), Th25 (23), and CD4+ cytotoxic T cells (CD4+ CTL) (24). Recently, we proposed a novel concept which suggests that pathological conditions re-shape physiological Treg into pathological Treg that have weakened immunosuppressive functions and increased plasticity (1). The following supporting evidence published by other investigators validate our proposed model: first, recent reports have identified Th1-like Treg phenotype in several pathological environments (25). For example, atherosclerosis-driven Treg plasticity leads to formation of a dysfunctional subset of IFN-γ secreting Th1-like Treg (26). In addition, presence of pro-inflammatory IL-17A cytokine secreting Treg had been reported (27); second, myocardial infarction increases Treg but their functions are compromised (28). This is an indication that Treg are converted to pathological Treg and can become less suppressive under pathological conditions; third, lymphomas “push” physiological Treg into four different types of “lymphoma Treg” (2); fourth, self-reactive T cells, termed anti-Treg, that can recognize MHC class I-restricted antigen peptide epitopes derived from Treg markers (such as indoleamine 2,3-dioxygenase (IDO), tryptophan 2,6-dioxygenase (TDO), programmed death ligand 1 (PD-L1), and forkhead box P3 (FOXP3)) were identified. This is a clear indication that there are endogenous mechanisms available to suppress Treg under various pathological conditions (29); and fifth, a recent report showed that a Treg transcription factor FOXP3 is highly expressed in tolerogenic dendritic cells (DCs) and program their tolerogenic influence, which modulate Treg and activate anti-Treg (30). It is accepted that Treg undergo phenotypic, and functional plastic changes into other Th subsets under pathological conditions (22, 31). However, the issue of whether Treg convert into other immune cell types such as APCs (antigen-presenting cells) when given the right condition remains unknown.

Despite recent significant progress in T cell research, there are several aspects of Th subset regulator expression that have not yet been explored: first, the expression profiles of all the Th subset regulators in tissues under physiological and pathological conditions, specifically in patients with metabolic cardiovascular diseases have not been studied; second, the issue of whether the expression of Th subset-promoting cytokines are modulated in vascular cells in response to pathological stress is not known; third, mechanistically, the issue of whether the master regulators of other Th subsets can control Treg plasticity had been poorly characterized; and fourth, whether plastic Treg can function as APCs is yet to be determined. To address these questions, we took a “panoramic view” at the tissue expression patterns of 61 identified Th subset regulators. Our novel working hypothesis is presented in Figure 1. Our results demonstrated that all the Th subset regulators are differentially expressed among tissues in physiological conditions. We also found that the expression of other Th subset master regulators control Treg plasticity to Th1 and APC-like Treg. Our findings provide novel insights into Th subset master regulators such as FOXP3, GATA3, BCL6, and HDAC6, suggesting that those signaling molecules can be potential therapeutic targets in the treatment of cancers, metabolic diseases, inflammation, tissue regeneration, and repair.

**MATERIALS AND METHODS**

**Tissue Expression Profiles of Genes Encoding Th Subset Regulators**

An experimental data mining strategy (Figure 2) was used to analyze the expression profiles of mRNA transcripts of Th subset regulator genes in 32 human tissues including heart and vasculature. We utilized experimentally verified mRNA expression in the EST (expressed sequence tag) databases of the National Institutes of Health (NIH)/National Center of Biotechnology Information (NCBI) UniGene (http://www.ncbi.nlm.nih.gov/sites/entrez?db=unigene) to determine the transcription profile of Th subset regulators in tissues of interest. Transcripts per million of genes of interest were normalized to that of housekeeping β-actin in each given tissue to calculate the arbitrary units of gene expression as we previously reported (7, 32). Confidence intervals of the expression variation of housekeeping genes were generated by calculating the mean plus two times that of the SD of the arbitrary units of gene expression in the EST database. To address these questions, we took a “panoramic view” at the tissue expression profiles of 61 identified Th subset regulators. Our results demonstrated that all the Th subset regulators are differentially expressed among tissues in physiological conditions. We also found that the expression of other Th subset master regulators control Treg plasticity to Th1 and APC-like Treg. Our findings provide novel insights into Th subset master regulators such as FOXP3, GATA3, BCL6, and HDAC6, suggesting that those signaling molecules can be potential therapeutic targets in the treatment of cancers, metabolic diseases, inflammation, tissue regeneration, and repair.

**Expression Profiles of Th Subset Regulators in Disease Models and Cell Activity**

Microarray datasets were collected from the NIH-NCBI-Geo DataSets (https://www.ncbi.nlm.nih.gov/gds/). These data
Physiological conditions – Th subset regulator expression in human tissues.

CD4+ T cell subset regulator genes are highly expressed in multiple healthy human tissues.

Eight CD4+ T cell subsets have different numbers of gene expression in different human tissues.

Details of each gene expression in multiple healthy human tissues.

Pathological conditions – Th subset regulator expression are modulated in diseases.

A. Metabolic diseases
B. Autoimmunity diseases
C. Physical injury
D. Th modulation by activated/diseased vascular cells
E. Plasticity of Treg
F. Plastic Treg cells and their pathways

FIGURE 1 | A novel working hypothesis: CD4+ T helper (Th) subset regulators are differentially expressed in normal tissues in physiological conditions; and Th subset regulator expression are modulated in various diseases and mutant mice (Th25 information is limited; therefore, Th25 is not included in this figure).

included the information of the expression level of Th subset regulators through experiments submitted directly to the NCBI Gene Expression Omnibus database. We used the gene expression data from the following microarray experimental settings: (1) metabolic diseases such as obesity (33), type 2 diabetes (34), failing heart (35), hyperlipidemic apolipoprotein E-deficient (ApoE−/−) mice (36), and familial hypercholesterolemia (37); (2) autoimmune diseases such as systemic lupus erythematosus (38) and psoriasis (39); (3) severe trauma (40) and burn injury (41); (4) vascular endothelial cells and vascular smooth muscle cells stimulated with proatherogenic stimuli; and (5) Treg in diseased and gene mutation conditions.

RESULTS

All the Th Subset Regulators Are Differentially Expressed in Various Human Tissues Including Heart and Vascular Tissues in Physiological Conditions

In response to the stimulation by several different inducing cytokines such as interferon-γ (IFN-γ), IL-12, and IL-4, naïve CD4+ T cells can be differentiated/polarized into at least eight terminally differentiated subsets including T helper cell 1 (Th1), Th2, Th9, follicular T (Tfh), Th17, Treg, Th22
**Fig 2** | Flow chart of database mining strategy and two parts of data organization. (A) Presents the key questions addressed by this study. (B) Determining the expression of Th subset regulators in tissues under physiological conditions. (C) Determining the expression of Th subset regulators under pathological conditions.
(1, 22), and Th25 (23) (Figure 1). An important question remains whether human tissues provide various stimulatory/suppressive environments that differentially regulate Th subset polarization/differentiation. We hypothesized that differentiation signals and immunogenic conditions of tissues regulate the expression of Th subset regulators in human tissues. To examine this hypothesis, we conducted an extensive literature survey (22, 23, 42) and collected total of 61 Th subset regulators (Table 1). These Th subset regulators included 20 Th subset transcription factors, 5 transcription activators, 1 transcription repressor, 2 signal transducers and transcription modulators, 20 cytokines, 5 lineage inducing factors, 6 cytokine/factor receptors, and 2 other membrane receptors (Table 1). We then examined the expression patterns of all 61 Th subset regulators in 32 human tissues as described in the Section “Materials and Methods.”

Based on the Th subset regulator expression amongst human tissues examined, we classified the tissues into following three groups: highly expressed (++), low expressed (+), and not expressed (−) as summarized in Table 2. Our analysis indicated that Th subset regulators are differentially expressed in 32 human tissues in physiological conditions (Figure S1 in Supplementary Material). Interestingly, Treg-specific transcription factor (TF) FOXP3 was expressed in trachea, thymus, spleen, mammary gland, lymph node, lung, eye, and blood. Out of these tissues, trachea highly expressed FOXP3 TF. Th1 TF TBX21 (T-bet) was only expressed in spleen, lymph nodes, and pancreas with the highest level recorded in spleen. Th2 TF GATA3 was expressed in 21 out of 32 tissues that were analyzed, including heart and vasculature with the high levels in adrenal gland, mammary gland, and placenta. Moreover, Th9 TF SPI1 (Pu.1) was expressed in 16 tissues with high expression levels in 11 tissues. Th7 TF BCL6 was expressed in 28 tissues with the high levels in adipose tissue, nerve, and trachea. Additionally, Th17 TF RORγt was expressed in 18 tissues with the high levels in bladder, cervix, liver, lymph node, muscle, thymus, and trachea. Th22 transcription regulator STAT3 was expressed in 31 tissues. Of note, the regulators of Th25 subset are unavailable for examination in this study. CD4 CTL are found within the traditional classification of Th0, Th1, Th2, TH17, CD4 intraepithelial lymphocyte (IEL) subsets with the characteristic expression of class I-restricted T cell associated molecule (CRTAM+) (24), which is outside of the scope of this study.

Immune privilege is the ability of tissues to actively regulate and direct immune responses that takes place in the tissue itself (43). We hypothesized that immune privilege status observed in certain human tissues may not allow Th subset regulators to be expressed. As shown in Table 3, we found that Th1 and Th2 regulators are expressed in every tissue except umbilical cord (Th1 and Th2) and esophagus (Th2). Some Th1 regulators are highly expressed in 13 human tissues including trachea, thymus, placenta, pancreas, muscle, mammary gland, lymph node, lung, heart, bone marrow, blood, and adipose tissue. In addition, we found that Th9, Th17, and Treg regulators are expressed in every tissue (Tables 4 and 5). Th22 regulators were expressed in many tissues except spleen, cervix, adrenal gland, and adipose tissue (Tables 2–6). Moreover, based on the variety of highly expressed Th subset regulators in any given human tissues, we constructed a tissue pyramid (Figure 3). Our data indicated that trachea, muscle, blood, lymph node, spleen, heart, kidney, nerve, and placenta are located in the top of the “tissue pyramid” as they express a large variety of Th subset regulators (Figure 3).

Furthermore, based on the relative numbers of each Th subset regulators expressed in human tissues, we discovered the following (Figure 4): (a) Treg regulators are highly expressed in brain, eye, lymph node, and muscle. (b) Th17 regulators are dominant in adrenal gland, cervix, liver, and trachea. (c) Th1 regulators are dominant in heart and spleen. (d) Th2 regulators are dominant in adipose tissue, bladder, bone marrow, eye, lung, placenta, skin, and vascular, which functionally relate to their allergy activities; (e) Tfh regulators are dominant in adipose tissue, intestine, and nerve. Of note, it was reported that Th1 is able to convert into Th1 and Th17. Future studies are needed to determine the tissue locations of those plastic Th subsets in addition to the classical tissue locations within and in proximity to germinal centers in secondary lymphoid organs and circulating blood (44). (f) Five human tissues including embryonic tissue, esophagus, prostate, umbilical cord, and uterus have either no or very low resident Th subset activities, which suggest that these tissues may have immune privilege status (32). Finally, (g) we found that four human tissues including blood, lymph node, muscle, and trachea are the most important hubs with the highest variety of Th subset regulator expression, suggesting their highest activities in these tissues. Two of the tissues such as muscle and trachea are our newly identified most active Th subset hubs in non-classical immune tissues.

Chronic Metabolic Diseases and Autoimmune Diseases Increase Multiple Th Subset Regulators but Decrease Treg Regulators; and Familial Hypercholesterolemia and Lupus Do Not Increase Th1 Regulators

Previously, we reported that the presence of CD4+ CD25+ Treg in proatherogenic mouse model apolipoprotein E-deficient (ApoE−/−) mice were significantly decreased (13). Moreover, we also suggested that pathological conditions re-shape physiological Tregs into pathological Tregs (1, 19). Here, we hypothesized that in addition to Treg regulation, the expression of all the Th subset regulators are modulated differentially in chronic metabolic diseases and autoimmune diseases compared to healthy conditions.

To test this hypothesis, we examined the gene expression data extracted from microarray experiments deposited in the NIH-Geo Datasets. These microarrays were conducted on insulin-resistant obese patients’ omental and subcutaneous adipose tissues. The results in the Table S1 in Supplementary Material showed that in omental and subcutaneous adipose tissues, insulin resistance inhibits the expression of Treg (forkhead family of transcription factor O1, FoxO1) and Th22 (ligand-activated helix-loop-helix transcription factor and aryl hydrocarbon receptor, AHR)
Table 1: 61 Genes involved in regulation of eight CD4+ T helper cell (Th) subsets that were focused in our study.

| Transcription factor (20) | Gene name | Common name | UniGene ID (Human) | UniGene ID (mouse) | Th Subset |
|---------------------------|-----------|-------------|--------------------|--------------------|-----------|
| AHR                       | Aryl hydrocarbon receptor | Hs.171189 | Mm.341377 | TH22 |
| ACT1                      | Act1      | N/A         | Mm.6872 | TH25 |
| BATF                      | BATF      | Hs.503964 | Mm.491223 | Treg |
| BACH2                     | BACH2     | Hs.269764 | Mm.347398 | TH2 |
| BCL6                      | BCL6      | Hs.478688 | Mm.233181 | TH2 |
| CMIP                       | c-MAF     | Hs.594095 | Mm.200692 | TH1 |
| EOMES                     | EOMES     | Hs.591663 | Mm.29891 | Treg |
| FOXO1                     | FOXO1     | Hs.307066 | Mm.338613 | Treg |
| FOXO3                     | FOXO3     | Hs.220960 | Mm.182291 | Treg |
| FOXP3                     | Foxp3     | Hs.247700 | Mm.131866 | TH2 |
| GATA3                     | Gata-3    | Hs.524134 | Mm.332607 | TH1 |
| HNF1A                     | TCF1      | Hs.654455 | Mm.4372 | TH1 |
| IRF4                      | IRF4      | Hs.401013 | Mm.277406 | TH1 |
| IKZF4                     | MAF       | Hs.532211 | Mm.358648 | Treg |
| MAZ                       | MAZ       | Hs.532211 | Mm.358648 | Treg |
| RORC                      | RORα      | Hs.256022 | Mm.4372 | TH17 |
| RUNX1                     | RUNX1     | Hs.170019 | Mm.378894 | TH1 |
| SPI1                      | SPI1      | Hs.502511 | Mm.1302 | TH9 |
| TBX21                     | T-bet     | Hs.272409 | Mm.94519 | TH1 |

| Transcription activator (5) | | | |
|-----------------------------|-----------|--------------------|-------------------|-----------|
| STAT1                       | STAT1     | Hs.743244 | Mm.277406 | TH1 |
| STAT3                       | STAT3     | Hs.463059 | Mm.249934 | TH9 |
| STAT4                       | STAT4     | Hs.80642 | Mm.1550 | TH1 |
| STAT3A                      | STAT5     | Hs.437058 | N/A | Treg |
| STAT6                       | STAT6     | Hs.524518 | Mm.121721 | Treg |

| Transcription repressor (1) | | | |
|-----------------------------|-----------|--------------------|-------------------|-----------|
| GFI1                        | GFI1      | Hs.73172 | Mm.2078 | TH2 |

| Signal transducers and transcriptional modulators (2) | | | |
|-------------------------------------------------------|-----------|--------------------|-------------------|-----------|
| SMAD2                     | SMAD2     | Hs.12253 | Mm.152699 | TH9, Treg |
| SMAD3                     | SMAD3     | Hs.727986 | Mm.7320 | TH9, Treg |

| Cytokine (20) | | | |
|---------------|-----------|--------------------|-------------------|-----------|
| CCL15         | CCL15     | Hs.272493 | N/A | TH22 |
| CCL17         | CCL17     | Hs.542424 | Mm.41988 | TH22 |
| IL2           | IL-2      | Hs.90879 | Mm.14190 | TH1, TH2, TH9, Treg |
| IL4           | IL-4      | Hs.73917 | Mm.276560 | TH2, TH9 |
| IL5           | IL-5      | Hs.2247 | Mm.4461 | TH2, TH9 |
| IL6           | IL-6      | Hs.654458 | Mm.1019 | TH9, TH17 |
| IL9           | IL-9      | Hs.960 | Mm.3006 | TH9 |
| IL10          | IL-10     | Hs.193717 | Mm.874 | Treg |
| IL12PB1*      | IL-12     | Hs.567294 | N/A | TH1 |
| IL13          | IL-13     | Hs.845 | Mm.1284 | TH2 |
| IL1B          | IL-17     | Hs.158979 | N/A | TH17 |
| IL17F         | IL-17F    | Hs.272295 | Mm.222807 | TH17 |
| IL21          | IL-21     | Hs.587559 | Mm.157689 | TH4, TH17 |
| IL22          | IL-22     | Hs.287369 | Mm.103585 | TH17 |
| IL23          | IL-23     | N/A | Mm.90154 | TH25 |
| IL25          | IL-25     | Hs.302036 | Mm.222632 | TH1 |
| IL27          | IL-27     | Hs.528111 | Mm.222632 | TH1 |
| IL10RB        | IL10Rβ    | Hs.654593 | Mm.4154 | TH22 |
| ICOS          | ICOS      | Hs.56247 | Mm.42044 | TH9 |
| INFγ          | INFγ      | Hs.856 | Mm.240327 | TH1 |

| Factors inducing lineage (5) | | | |
|------------------------------|-----------|--------------------|-------------------|-----------|
| CXCR5                       | CXCR5     | Hs.113916 | Mm.6246 | TFH |
| IDO1                        | Indoleamine 2,3-dioxygenase 1 | Hs.840 | Mm.392 | TH2 |
| MVD68                       | MyD88     | Hs.82116 | Mm.213003 | TH17 |
| MTOR                        | mTOR      | Hs.338207 | Mm.21158 | Treg |
| TGIF1                       | TGFβ      | Hs.373550 | Mm.101034 | TH9, TH17, Treg |

(Continued)
TABLE 1 | Continued

| Receptor (6) | Common name | UniGene ID (Human) | UniGene ID (mouse) | Th Subset |
|-------------|-------------|--------------------|--------------------|-----------|
| RARA | RARA | Hs.654583 | Mm.439744 | TH1 |
| CCR3 | CCR3 | Hs.506190 | Mm.57050 | TH9 |
| CCR4 | CCR4 | Hs.184926 | Mm.1337 | TH2 |
| CXCR3 | CXCR3 | Hs.198252 | Mm.12876 | TH1, TH9 |
| CCR6 | CCR6 | Hs.44648 | Mm.8007 | TH17 |
| CCR8 | CCR8 | Hs.113222 | Mm.442098 | TH2 |

| Others (2) | CD28 | CD28 | Hs.443123 | Mm.255003 | Treg |
|-----|-----|-----|---------|---------|-----|
| CTLA4 | CTLA4 | Hs.247824 | Mm.390 | Treg |

| Others (2) | CD28 | CD28 | Hs.443123 | Mm.255003 | Treg |
|-----|-----|-----|---------|---------|-----|
| CTLA4 | CTLA4 | Hs.247824 | Mm.390 | Treg |

| RARA | RARA | Hs.654583 | Mm.439744 | TH1 |
|-----|-----|---------|---------|-----|
| CCR3 | CCR3 | Hs.506190 | Mm.57050 | TH9 |
| CCR4 | CCR4 | Hs.184926 | Mm.1337 | TH2 |
| CXCR3 | CXCR3 | Hs.198252 | Mm.12876 | TH1, TH9 |
| CCR6 | CCR6 | Hs.44648 | Mm.8007 | TH17 |
| CCR8 | CCR8 | Hs.113222 | Mm.442098 | TH2 |

| Others (2) | CD28 | CD28 | Hs.443123 | Mm.255003 | Treg |
|-----|-----|-----|---------|---------|-----|
| CTLA4 | CTLA4 | Hs.247824 | Mm.390 | Treg |

Severe Trauma Injury Increases Th2, Th9, Tfh, and Th17 Subset Regulators but Decreases Th1 and Treg Regulators in Blood; and Burn Injury Decreases All Th Subset Regulators Except Th22 Regulators

It has been reported that severe trauma injury (40) and burn injury (41) cause a genomic storm that lead to suppression of the genes involved in adaptive immunity. Thus, we hypothesized that the expression of Th subset regulators are modulated in severe trauma and burn injury. As summarized in Table 9, we found that severe trauma increases the expression of Th2, Th9, and Th17 subset regulators, but decreases the expression of Th1 and Treg regulators, suggesting that severe trauma decreases pro-inflammatory Th1 and anti-inflammatory/immunosuppressive Treg at the same time, which were correlated well with decreased presence of Th1 and Treg in smoke inhalation-induced lung injury (48). By comparison, we found that burn injury in patients decreases the expression of all the Th subset regulators except Th22 regulators (Table S11 in Supplementary Material). IL-22 is produced by a subset of human skin-homing memory T cells (49). Also, IL-22 is a master homeostatic cytokine preserving the integrity of boundary organs and tissues, especially for epithelial cell regeneration (50). Therefore, for the first time, our results have demonstrated that the expression of IL-22 generating Th22 regulators sustain burn injury-induced heavy stress and may play a critical role for tissue recovery from burn injury.

Vascular Cells Are Functional As Innate Immune Cells, Express Numerous Th Subset-Promoting Cytokines and Stimulate Th Regulator Expression Other than Treg Regulator Expression

We recently proposed a new paradigm that endothelial cells are conditional innate immune cells, which actively participate in both innate and adaptive immune responses (52). To consolidate the new model, we hypothesized that vascular cells respond to cardiovascular disease risk factors and endogenous metabolites-derived danger signals and differentially modulate Th subset
| Gene/tissue          | Adipose | Adrenal gland | Bladder | Blood | Bone marrow | Brain | Cervix | Embryonic tissue | Esophagus | Eye | Heart | Intestine | Kidney | Liver | Lung | Lymph node | Mammary gland | Muscle | Nerve | Ovary | Pancreas | Placenta | Prostate | Skin | Splen | Stomach | Thymus | Trachea | Unial | Uterus | Vascular |
|---------------------|---------|---------------|---------|-------|-------------|-------|--------|------------------|-----------|-----|-------|----------|--------|-------|------|------------|-------------|--------|-------|-------|---------|---------|---------|------|-------|---------|--------|---------|-------|-------|---------|
| **AHR**             | +       | +             | +       | +     | +           | +     | +      | +                | +         | +   | +     | +        | +      | +     | +    | +          | +           | +      | +     | +     | +       | +       | +       | +    | +     | +       | +      | +       |
| **BATF**            | +       |               |         |       |             |       |        |                  |           |     |       |          |        |       |      |             |             |       |       |       |         |         |         |      |       |         |        |         |
| **BACH2**           | +       |               |         |       |             |       |        |                  |           |     |       |          |        |       |      |             |             |       |       |       |         |         |         |      |       |         |        |         |
| **BCL6** (Th1)      | ++      | +             | +       | +     | +           | +     | +      | +                | +         | +   | +     | +        | +      | +     | +    | +          | +           | +      | +     | +     | +       | +       |
| **CMIP**            | +       | +             | +       |       | +           | +     | +      | +                | +         | +   | +     | +        | +      | +     | +    | +          | +           | +      | +     | +     | +       | +       |
| **EOMES**           | +       |               |         |       |             |       |        |                  |           |     |       |          |        |       |      |             |             |       |       |       |         |         |         |      |       |         |        |         |
| **FOXO1**           | +       | +             | +       |       | +           | +     | +      | +                | +         | +   | +     | +        | +      | +     | +    | +          | +           | +      | +     | +     | +       | +       |
| **FOXO3** (Treg)    | +       | +             | +       |       | +           | +     | +      | +                | +         | +   | +     | +        | +      | +     | +    | +          | +           | +      | +     | +     | +       | +       |
| **GATA3** (Th2)     | +       | +             | +       |       | +           | +     | +      | +                | +         | +   | +     | +        | +      | +     | +    | +          | +           | +      | +     | +     | +       | +       |
| **HNF1A**           | +       | +             | +       |       | +           | +     | +      | +                | +         | +   | +     | +        | +      | +     | +    | +          | +           | +      | +     | +     | +       | +       |
| **IRF4**            | +       | +             | +       |       | +           | +     | +      | +                | +         | +   | +     | +        | +      | +     | +    | +          | +           | +      | +     | +     | +       | +       |
| **IKZF4**           | +       | +             | +       |       | +           | +     | +      | +                | +         | +   | +     | +        | +      | +     | +    | +          | +           | +      | +     | +     | +       | +       |
| **MAF**             | +       | +             | +       |       | +           | +     | +      | +                | +         | +   | +     | +        | +      | +     | +    | +          | +           | +      | +     | +     | +       | +       |
| **RORC** (Th17)     | +       | +             | +       |       | +           | +     | +      | +                | +         | +   | +     | +        | +      | +     | +    | +          | +           | +      | +     | +     | +       | +       |
| **RORA**            | +       | +             | +       |       | +           | +     | +      | +                | +         | +   | +     | +        | +      | +     | +    | +          | +           | +      | +     | +     | +       | +       |
| **RUNX3**           | +       | +             | +       |       | +           | +     | +      | +                | +         | +   | +     | +        | +      | +     | +    | +          | +           | +      | +     | +     | +       | +       |
| **SP1** (Th9)       | +       | +             | +       |       | +           | +     | +      | +                | +         | +   | +     | +        | +      | +     | +    | +          | +           | +      | +     | +     | +       | +       |
| **TBX21** (Th1)     | +       | +             | +       |       | +           | +     | +      | +                | +         | +   | +     | +        | +      | +     | +    | +          | +           | +      | +     | +     | +       | +       |
| **STAT1**           | +       | +             | +       |       | +           | +     | +      | +                | +         | +   | +     | +        | +      | +     | +    | +          | +           | +      | +     | +     | +       | +       |
| **STAT3** (Th2)     | +       | +             | +       |       | +           | +     | +      | +                | +         | +   | +     | +        | +      | +     | +    | +          | +           | +      | +     | +     | +       | +       |
| **STAT4**           | +       | +             | +       |       | +           | +     | +      | +                | +         | +   | +     | +        | +      | +     | +    | +          | +           | +      | +     | +     | +       | +       |
| **STAT5A**          | +       | +             | +       |       | +           | +     | +      | +                | +         | +   | +     | +        | +      | +     | +    | +          | +           | +      | +     | +     | +       | +       |
| **STAT6**           | +       | +             | +       |       | +           | +     | +      | +                | +         | +   | +     | +        | +      | +     | +    | +          | +           | +      | +     | +     | +       | +       |
| **GFI1**            | +       | +             | +       |       | +           | +     | +      | +                | +         | +   | +     | +        | +      | +     | +    | +          | +           | +      | +     | +     | +       | +       |
| **SMAD2**           | +       | +             | +       |       | +           | +     | +      | +                | +         | +   | +     | +        | +      | +     | +    | +          | +           | +      | +     | +     | +       | +       |
| **SMAD3**           | +       | +             | +       |       | +           | +     | +      | +                | +         | +   | +     | +        | +      | +     | +    | +          | +           | +      | +     | +     | +       | +       |
| **CCL5**            | +       | +             | +       |       | +           | +     | +      | +                | +         | +   | +     | +        | +      | +     | +    | +          | +           | +      | +     | +     | +       | +       |
| **CCL17**           | +       | +             | +       |       | +           | +     | +      | +                | +         | +   | +     | +        | +      | +     | +    | +          | +           | +      | +     | +     | +       | +       |
| **IL2**             | +       | +             | +       |       | +           | +     | +      | +                | +         | +   | +     | +        | +      | +     | +    | +          | +           | +      | +     | +     | +       | +       |
| **IL4**             | +       | +             | +       |       | +           | +     | +      | +                | +         | +   | +     | +        | +      | +     | +    | +          | +           | +      | +     | +     | +       | +       |
| **IL5**             | +       | +             | +       |       | +           | +     | +      | +                | +         | +   | +     | +        | +      | +     | +    | +          | +           | +      | +     | +     | +       | +       |
| **IL6**             | +       | +             | +       |       | +           | +     | +      | +                | +         | +   | +     | +        | +      | +     | +    | +          | +           | +      | +     | +     | +       | +       |
| **IL9**             | +       | +             | +       |       | +           | +     | +      | +                | +         | +   | +     | +        | +      | +     | +    | +          | +           | +      | +     | +     | +       | +       |
| **IL10**            | +       | +             | +       |       | +           | +     | +      | +                | +         | +   | +     | +        | +      | +     | +    | +          | +           | +      | +     | +     | +       | +       |
| **L12RB1**          | +       | +             | +       |       | +           | +     | +      | +                | +         | +   | +     | +        | +      | +     | +    | +          | +           | +      | +     | +     | +       | +       |
| **L13**             | +       | +             | +       |       | +           | +     | +      | +                | +         | +   | +     | +        | +      | +     | +    | +          | +           | +      | +     | +     | +       | +       |

(Continued)
| Gene/tissue | Adipose | Adrenal gland | Bladder | Blood | Bone | Bone marrow | Brain | Cervix | Embryonic tissue | Esophagus | Eye | Heart | Intestine | Kidney | Liver | Lung | Lymph node | Mammary gland | Muscle | Nerve | Ovary | Pancreas | Placenta | Prostate | Skin | Spleen | Stomach | Thymus | Trachea | Umbilic chord | Uterus | Vascular |
|-------------|---------|---------------|---------|-------|------|------------|------|--------|-----------------|-----------|-----|-------|----------|-------|------|-----|------------|-------------|--------|-------|-------|--------|---------|---------|-----|-------|---------|--------|---------|----------------|------|---------|
| IL7B        | ++      | +             | ++      | +     | +    | ++         | +    | +      | +               | ++        | +   | +     | +        | +     | +    | +   | +          | +           | +      | +     | +     | +      | +       | +       | +   | +      | +       | +      | +       | +               | +    | +       |
| IL17F       | ++      |               |         |       |      |            |      |         | +               |          |     |       |          |       |      |     |            |             | +      |       |       |         |         |         |     |       |         |       |         | +               |     |         |
| IL22        | ++      |               |         |       |      |            |      |         | +               | +         |     |       |          |       | +    |     |            |             |        |       |       |         |         |         |     |       |         |       |         | -               |     |         |
| IL27        | ++      |               |         |       |      |            |      |         | +               | +         |     |       |          |       |      |     |            |             | +      |       |       |         |         |         |     |       |         |       |         | -               |     |         |
| L10F8       | +       | +             | +       | +     | +    | ++         | +    | +      | +               | ++        | +   | +     | +        | +     | +    | +   | +          | +           | +      | +     | +     | +      | +       | +       | +   | +      | +       | +      | +       | +               | +    | +       |
| ICOS        | +       | +             | ++      | +     | +    | +          | +    | +      | +               | +         | +   | +     | +        | +     | +    | +   | +          | +           | +      | +     | +     | +      | +       | +       | +   | +      | +       | +      | +       | +               | +    | +       |
| IFNG        | ++      |               |         |       |      |            |      |         | +               | +         |     |       |          |       | +    |     |            |             |        |       |       |         |         |         |     |       |         |       |         | -               |     |         |
| CXCR5       | ++      |               |         |       |      |            |      |         | +               | +         |     |       |          |       |      |     |            |             | +      |       |       |         |         |         |     |       |         |       |         | -               |     |         |
| MYD88       | ++      |               |         |       |      |            |      |         | +               | +         |     |       |          |       |      |     |            |             | +      |       |       |         |         |         |     |       |         |       |         | -               |     |         |
| IDO1        | +       | +             | +       | +     | +    | +          | +    | +      | +               | +         | +   | +     | +        | +     | +    | +   | +          | +           | +      | +     | +     | +      | +       | +       | +   | +      | +       | +      | +       | +               | +    | +       |
| MTOR        | +       | +             | +       | +     | +    | +          | +    | +      | +               | +         | +   | +     | +        | +     | +    | +   | +          | +           | +      | +     | +     | +      | +       | +       | +   | +      | +       | +      | +       | +               | +    | +       |
| TGIF1       | +       | +             | +       | +     | +    | +          | +    | +      | +               | +         | +   | +     | +        | +     | +    | +   | +          | +           | +      | +     | +     | +      | +       | +       | +   | +      | +       | +      | +       | +               | +    | +       |
| RARA        | +       | +             | +       | +     | +    | +          | +    | +      | +               | +         | +   | +     | +        | +     | +    | +   | +          | +           | +      | +     | +     | +      | +       | +       | +   | +      | +       | +      | +       | +               | +    | +       |
| CCR3        | ++      |               |         |       |      |            |      |         | +               | +         |     |       |          |       |      |     |            |             | +      |       |       |         |         |         |     |       |         |       |         | -               |     |         |
| CCR4        | ++      |               |         |       |      |            |      |         | +               | +         |     |       |          |       |      |     |            |             | +      |       |       |         |         |         |     |       |         |       |         | -               |     |         |
| CXCR3       | +       |               |         |       |      |            |      |         | +               | +         |     |       |          |       |      |     |            |             | +      |       |       |         |         |         |     |       |         |       |         | -               |     |         |
| CCR6        | +       |               |         |       |      |            |      |         | +               | +         |     |       |          |       |      |     |            |             | +      |       |       |         |         |         |     |       |         |       |         | -               |     |         |
| CCR8        | ++      |               |         |       |      |            |      |         | +               | +         |     |       |          |       |      |     |            |             | +      |       |       |         |         |         |     |       |         |       |         | -               |     |         |
| CTLA4       | +       |               |         |       |      |            |      |         | +               | +         |     |       |          |       |      |     |            |             | +      |       |       |         |         |         |     |       |         |       |         | -               |     |         |

Treg transcription factor Foxp3 is expressed in trachea, thymus, spleen, mammary gland, lymph nodes, lung, eye, and blood; but the expression of Th1 transcription factor Tbx21 is limited to spleen, lymph node, and pancreas.

* "++" Human tissue with detectable gene expressions in the NIH-NCBI-UniGene database.

* "+" Human tissue with high gene expressions (X2D > 4.45).

* Transcription factor associated with Th subsets were highlighted with red fonts.
TABLE 3 | Th1 regulators are expressed in every tissue except umbilical cord; and Th2 regulators are expressed in every tissue except umbilical cord and esophagus.

---

regulator expression compared to healthy condition. As summarized in Table 10, we found that aortic endothelial cells activated by proatherogenic stimuli including lipopolysaccharide (LPS) (8), oxidized low-density lipoprotein (oxLDL) (53), and oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (oxPAPC) upregulate more effector Th subset regulators than Treg regulators (Table S12 in Supplementary Material). In addition, we found that vascular smooth muscle cells (VSMCs), in response to pro-inflammatory stimuli such as tumor necrosis factor-α (TNF-α), and a combination of TNF-α and lymphotoxin beta-receptor (α-LTβR) monoclonal antibody (54) upregulate more Th1, Th9, Th17 regulators than Treg regulators (Table S13 in Supplementary Material). These results suggest that vascular cells including endothelial cells and VSMCs contribute more to non-Treg Th subset development than Treg development in pro-inflammatory conditions.

GATA3 and HDAC6 Promote, but BCL6 Inhibits Th Subset Regulator Expression in Treg, and Regulate Treg Plasticity and Heterogeneity

It has been reported that Treg stability can be undermined or endorsed by different type 1 cytokines (55). Treg transcriptome
Xu et al. Transcription Factors and Treg Plasticity

Frontiers in Immunology | www.frontiersin.org January 2018 | Volume 9 | Article 45

is not stable, which contributes to Treg plasticity in gene transcription and immunosuppressive function (1). For example, atherosclerosis-driven Treg plasticity leads to formation of a dysfunctional subset of plastic Th1 cytokine interferon-γ (IFN-γ) Th1/Treg (26). In addition, IL-17A-secreting Treg was also identified (27). Moreover, myocardial infarction increases Treg...
but their function is compromised (28). Thus, we hypothesize that non-Treg Th subset-associated transcription factors not only regulate the development of non-Treg Th subsets but also functionally collaborate with Treg transcription factor FOXP3 in suppression of other Th subset regulator expression in Treg, and maintain Treg identity.
To test this hypothesis, we examined the expression of Th subset regulators in Treg in diseased conditions and in the presence of the mutations of various Treg-related regulators. As summarized in Table 11, we found that diabetes “switch” Treg to express other Th subset regulators, which is correlated with recent reports on plastic Treg in type 1 diabetes (56) and autoimmune arthritis (57). In addition, we also found that induced Treg are less likely than natural Treg to express non-Treg Th subset regulators except Th1 cytokine IFN-γ. Our results suggest that induced Treg have higher probability than natural Treg to become IFN-γ-secreting Treg rather than other Th subsets, which was not reported in the original paper (58). Moreover, deficiency of Treg in Foxp3 mutant Scurfy mice promotes the expression of other Th subset regulators, especially Th1 transcription factors such as Tbx21, transcription factor Eomesodermin (Eomes) (59), and Th22 regulator Ahr. This suggests that Foxp3 is functional in suppressing the expression of Th1 and Th22 subset regulators in Treg; and Foxp3-deficient Treg do not revert into conventional effector CD4+ T cells but constitute a unique cell subset (60).

Multiple factors “lock in” the transcriptional signature of Treg (61). Along the same line, we found that X-box binding protein 1 (Xbp1, a bZIP domain transcription factor) (61), Gata-binding factor 1 (Gata1, a transcription factor) (61), microRNA processing enzyme Dicer (62), cytotoxic T-lymphocyte-associated protein 4 (Ctla4) (63), and peroxisome proliferator-activated receptor gamma (PPARγ) (64) can also inhibit the expression of other Th subset regulators in Treg, and maintain Treg identity. This observation is similar to the previous report that showed impaired presence of Treg in PPARα KO mice (65).

Finally, we found that Th2-associated transcription factor Gata3 globally promotes the expression of Th1-associated transcription factors Tbx21, Th17-associated TF Rorc, Treg-transcription factors FoxO3 and FoxO1, and Tfh-associated TF BCL6 in Treg (Table S24 in Supplementary Material). Of note, functional counteraction of Foxp3 and Gata3 was reported previously (66), but our findings of Gata3 promoting the expression of Tbx21, Rorc, and BCL6 are novel.

Our previous paper reported that Treg have high expression of epigenetic master gene histone deacetylase 6 (HDAC6) than other T cells (19, 20). However, our results here showed that HDAC6 promotes the expression of Th1-associated TF Tbx21, Th17-associated TF Rora, Treg-transcription factors FoxO3 and FoxO1, and Tfh-associated TF BCL6 in Treg (Table S24 in Supplementary Material). Of note, functional counteraction of Foxp3 and Gata3 was reported previously (66), but our findings of Gata3 promoting the expression of Tbx21, Rorc, and BCL6 are novel.

In order to find out which pathways are involved in Gata3, Bcl6, and HDAC6 regulation of Treg plasticity, we used the Ingenuity Pathway Analysis to determine the pathways involved. As shown in Figure 5, we found that among three gene deficiencies-induced pathways in Treg, all the three pathways regulate Th1 polarization, Th1 and Th2 activation processes, and T helper cell differentiation. Each of three master gene mutations have four to
five specific pathways and have five to six pathways shared with other master genes regulated pathways. These results suggest that: first, GATA3 is not only responsible for developing Th2; BCL6 is not only responsible for developing Th subset, GATA3 also promotes Treg plasticity; second, in contrast to GATA3, BCL6 collaborates well with Treg-specific TF FOXP3 in suppression of other Th subset regulator expression in Treg; and third, HDAC6-mediated removal of histone acetylation, presumably at specific amino acid residue(s) in histones, promotes Treg plasticity and Treg heterogeneity.
### TABLE 7 | Metabolic cardiovascular diseases increase multiple Th subset regulator expression but inhibit Treg regulator expression (Tables S1–S6 in Supplementary Material).

| Disease                                      | Tissue                                      | Result                                                                                                                                                                                                 |
|----------------------------------------------|---------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Obesity                                      | Omental and subcutaneous adipose            | Insulin resistance inhibits the expression of Treg and Th22 regulators but promotes the other Th subset regulators in patients’ visceral adipose tissues                                                    |
| Type2 diabetes and hyperlipidemia            | Liver, adipose tissues, and spleen          | Type 2 diabetes and hyperlipidemia promote multiple Th subset gene expressions                                                                                                                                 |
| Failing heart                                | Heart                                       | Failing heart induced in apolipoprotein E-deficient (Apoe−/−) mice with PPARγ agonist rosiglitazone significantly increase the expressions of Th subset regulators                                                                 |
| ApoE−/− mice                                 | Aorta                                       | Hyperlipidemia promotes Th subset gene expressions in aortic adventitia                                                                                                                                 |
| ApoE−/− mice                                 | Blood                                       | Hyperlipidemia in ApoE−/− blood increase a few Th subset genes in comparison to wild-type mouse blood                                                                                                     |
| Familial hypercholesterolemia                | CD3 T cell                                  | Familial hypercholesterolemia upregulate all the Th subset genes except that of Th1                                                                                                                                 |

### TABLE 8 | Autoimmunity diseases promote multiple Th subset regulators but inhibit Treg regulators (Tables S7–S9 in Supplementary Material).

| Disease                                      | Tissue                                      | Result                                                                                                                                                                                                 |
|----------------------------------------------|---------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Systemic lupus erythematosus                 | Blood                                       | Increase Th2, Th9, and TFH subset genes but decrease Th1 and Treg genes                                                                                                                                   |
| Systemic lupus erythematosus                 | Blood                                       | Th1 cytokine IFN-γ therapy in lupus patients increases more Th1 and Th17 subsets than non-treatment control in blood cells                                                                                   |
| Psoriasis                                    | Skin biopsy                                 | Induces all the Th subset genes except Treg genes                                                                                                                                                        |

### TABLE 9 | Similar to lupus patients, severe trauma increase Th2, Th9, TFH, and Th17 subset regulator expressions but decreases Th1 and Treg regulator expressions; but burn injury decreases all the Th subset regulators except Th22 regulators (Tables S10 and S11 in Supplementary Material).

| Disease                                      | Tissue                                      | Result                                                                                                                                                                                                 |
|----------------------------------------------|---------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Severe trauma                                | Increase Th2, Th9, TFH, and Th17 subsets but decreases Th1 and Treg |
| Burn injury                                  | Burn Injury in patients decreases all the Th subsets except Th22 |

### TABLE 10 | As innate immune cells, vascular cells secrete numerous Th subsets-promoting cytokines and induce the expression of Th subset regulators except Treg regulators (Tables S12 and S13 in Supplementary Material).

| Disease                                      | Tissue                                      | Result                                                                                                                                                                                                 |
|----------------------------------------------|---------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Atherosclerosis                              | Aortic endothelial cells                    | Aortic endothelial cells activated by pre-atherogenic and stimulate to secrete Cytokines that promote more effector Th subsets than Treg                                                                 |
| Atherosclerosis and myocardial infarction    | Smooth muscle cells                         | Vascular smooth muscle cells in response to inflammatory stimulates, secrete cytokines that promote more Th1, Th9, TFH, Th17 than Treg                                                                  |

### Gata3 and Bcl6 Inhibit the Expression of MHC Class II, and T Cell Co-Signaling Receptors in Treg and “Trans-Differentiate” Treg into Antigen-Presenting Cell (APC)-Like Treg

Recent reports showed that an increased number of cell types that are capable of acting as atypical antigen-presenting cells (APC) and present antigens to major histocompatibility complex (MHC) class II molecules to CD4 + T cells (69). CD4 + T cells are among atypical APCs. However, it is unknown whether plastic Treg can serve as atypical APC. We hypothesize that plastic Treg not only change into pro-inflammatory cytokine IFN-γ-secreting Th1-like Treg but also “trans-differentiate” into atypical APC.

It has been well accepted that MHC class II molecules present MHC II-restricted antigen epitopes to bind to T cell antigen receptor (TCR) to deliver the signal 1 for T cell activation (10). We examined whether MHC class II molecules are upregulated in plastic Treg. As shown in Table 12A, among 14 MHC class II molecules we found in the NIH-NCBI-Gene database, seven MHC class II molecules are upregulated in Gata3 KO Treg. In addition, we also found that five MHC class II molecules are upregulated in Bcl6 KO Treg; and five MHC class II molecules are downregulated in Hdac6 KO Treg, suggesting that Gata3 and Bcl6 inhibit MHC class II molecule expression in Treg, but HDAC6 promotes the expression of MHC class II molecules in Treg.

Moreover, it has been well-characterized that T cell co-signaling receptors including co-stimulation receptors and...
Several master regulators, including Foxp3, Xbp1, GATA1, CTLA-4, GATA3, BCL6, HDAC6, and PPARγ, modulate Th subset regulator expressions in Treg and other Th subsets.

| Conditions              | Tissue                  | Result                                                                 |
|------------------------|-------------------------|------------------------------------------------------------------------|
| Plasticity of Treg     | Spleen                  | Diabetes “switch” Treg to express other Th subset genes                 |
|                        |                         | Induced Treg are less likely to express Th subset genes except IFNγ relative to natural Treg. This suggest that induced Treg shows less plasticity than natural Treg. Induced Treg have higher potential than natural Treg to become IFNγ secreting Treg. |
| Scurfy mutation Foxp3−/−| Lymph node cells        | Deficiency of Treg in Scurfy mice promotes the development of other Th subsets in CD4+ T cell populations |
|                        | T cell                  | CD4+ T cells in Foxp3−/− scurfy mice require IL-2 to express Th subset genes |
| Xbp1 knockout          | Spleen                  | MicroRNA processing enzyme Dicer inhibits other Th subset gene expression |
| Gata1 knockout         | T cell                  | CTLA-4 inhibits Th subset gene expression but promotes IL-2 and other Treg gene expression |
| Gata3 knockout         | Treg                    | Gata3 promotes Th subset gene expression in Treg and Treg plasticity |
| Bcl6 and HDAC6         | Lymph nodes             | Bcl6 and HDAC6 inhibits Th subset gene expression in Treg and Treg plasticity |
| Treg-Ppary, Mut        | Visceral adipose tissue | Treg-specific PPARγ INHIBITS Th subset gene expression in adipose tissue and lymph node |

**FIGURE 5** The Venn diagram analysis. The Venn diagram shows that Treg plasticity regulators Gata3, Bcl6, and Hdac6 shre Th1 pathway and Th differentiation pathways.

Co-inhibition receptors bind to the intrinsic co-receptors on the effector T cell surface to trigger the signal 2 pathways for T cell activation (70–72). Thus, we examined whether the expression of T cell co-signaling receptors are upregulated in Gata3−/− Treg, Bcl6−/− Treg, and/or Hdac6−/− Treg. As shown in Table 12B, we found that: first, among 28 co-signaling receptors expressed on the cell surface of classical APCs (70–72), co-stimulation receptor 4-1BBL is upregulated in Hdac6 KO Treg; second, co-stimulation receptor LIGHT is upregulated in Gata3 KO Treg; third, co-stimulation receptors CD48, B7-1 (CD80), CD112, co-inhibition receptors galectin 9 and B7-DC are upregulated in Bcl6 KO Treg; and fourth, one co-inhibition receptor HVEM is downregulated in Hdac6 KO Treg, suggesting that Hdac6, Bcl6 and Gata3 inhibit the expression of co-signaling receptors in Treg (Table 12C).
note, these results showed that co-stimulation receptor 4-1BB is upregulated but five MHC class II molecules are downregulated in the Hdad6 KO Treg, suggesting that HDAC6 is not potent in regulating the Treg changes to atypical APC. Taken together, our results showed that (1) Gata3 and Bcl6 collaborate in inhibiting Treg plasticity and conversion into atypical APC; (2) mutations of Gata3 and Bcl6 “trans-differentiate” Treg into atypical APC; (3) Bcl6 inhibit Treg plasticity into Th1-like Treg and atypical APC but Hdad6 only promotes Treg plasticity into Th1-like Treg; and (4) GATA3 determine the fate of plastic Treg by controlling whether it will convert in to either Th1-Tregor APC-Treg (Figure S2 in Supplementary Material).

### DISCUSSION

In last 30 years, significant progress has been made in understanding of CD4 + T cells. Naïve CD4 + T cells can be differentiated/polarized into at least nine or 10 terminally differentiated subsets including Th1, Th2, Th9, Thfh (21), Th17, Treg, Th22 (1, 22), Th25 (23), CD4 + cytotoxic T cells (CD4 + CTL) (24) as well as innate lymphoid cell subsets (73). However, several important questions remain to be addressed including: (a) the tissue expression profile of Th subset regulators in human tissues; (b) how Th subset regulators are globally changed in various diseases; and (c) in addition to converting into Th1 and Th17 that have been reported, whether Treg plasticity can enhance T cell immune responses by acting as antigen-presenting cells (APC-Treg).

To address these issues, we took an experimental data mining approach that we pioneered (32, 74, 75) and examined the panoramic tissue expression patterns of as many as 61 Th subset

---

**Table 1** The mutations of three master regulators such as GATA3, BCL6 and HDAC6 modulate the expression of MHC class II molecules (signal 1 for T cell activation) and co-stimulation/co-inhibition receptors (signal 2 for T cell activation) in Treg.

(A) Treg plasticity regulators GATA3−/−, BCL6−/− upregulate, and HDAC6−/− downregulate the expression of mouse major histocompatibility complex (MHC) genes in the Treg, suggesting that the plastic Treg become antigen-presenting cell (APC)-like Treg to deliver the signal #1 to activate T effector cells.

| Official symbol | Gene ID | GSE39864 | GSE40493 | GSE27896 |
|-----------------|---------|-----------|-----------|-----------|
|                 | GATA3   | BCL6      | HDAC6     |
| Cd74            | 16149   | 1.33      | 5.16      |           |
| Cita            | 12265   |           |           |           |
| H2-Aa           | 14960   | 1.45      | 1.99      | −1.24     |
| H2-Abl          | 14961   | 1.42      | 2.39      |           |
| H2-DMa          | 14998   | 1.45      |           | −1.38     |
| H2-DMb1         | 14999   |           |           |           |
| H2-DMb2         | 15000   | 1.22      |           | −1.34     |
| H2-Es-ps        | 100054404 |          |           |           |
| H2-Eb1          | 14969   | 1.41      | 1.47      | −1.23     |
| H2-Eb2          | 381091  | 1.5       |           |           |
| H2-K1           | 14972   |           | 1.6       |           |
| H2-Oa           | 15001   | 1.48      |           | −1.66     |
| Mr1             | 15064   |           |           |           |

GSE 39864 (Gata3 KO vs WT T-reg), GSE 40493 (Bcl6 KO vs WT T-reg), GSE 27896 (Hdad6 KO vs WT T-reg).

(B) Treg can convert to antigen-presenting cell (APC)-like Treg and upregulate APC-expressed T cell co-stimulation/co-inhibition receptors to deliver the signal 2 to activate T effector cells.
Treg with increased plasticity can act as “antigen-presenting cell (APC)-like Treg” by upregulating co-stimulation co-receptors such as LIGHT, 4-1BB, CD48, B7-1, and CD112, and downregulating co-inhibition co-receptor HVEM.

The co-signaling receptors shown in bold letters were upregulated in T-reg with increased plasticity.

| Co-stimulator | Co-inhibitor |
|---------------|--------------|
| **Antigen-presenting cell** | **Co-inhibitor** |
| B7-H2 | Galectin9 |
| CD70 | CD113 |
| **LIGHT** | **HVEM** |
| CD40 | B7-DC |
| 4-1BBL | B7-H1 |
| OX40L | B7-H2 |
| TL1A | VISTA |
| GITRL | HHLA2 |
| CD30L | BTNL2 |
| TIM4 | |
| SLAM | |
| **CD48** | |
| SEMA4A | |
| CD58 | |
| **Altered** | |
| **B7-1** | |
| **B7-2** | |
| **CD155** | |
| **CD112** | |
| **Co-stimulator** | |
| ICOS | CTLA4/CD28 |
| HVEM | TIGHT/CD226 |
| CD27 | |
| CD40L | |
| 4-1BB | |
| OX40 | |
| DR3 | |
| GITR | |
| CD30 | |
| TIM1 | |
| SLAM | |
| **CD2/2B4** | |
| TIM2 | |
| CD2 | |

Regulators in physiological and pathological conditions. We made the following findings: (1) All the Th subset regulators are differentially expressed in various human tissues including heart and vascular tissues at physiological conditions; (2) Chronic metabolic diseases and autoimmune diseases increase multiple Th subset regulators but decrease Treg regulators. Familial hypercholesterolemia and lupus do not increase Th1 regulators; (3) Severe trauma increases Th2, Th9, Th17, and Th17 subset regulators but decreases Th1 and Treg regulators in blood. In contrast, burn injury decreases all Th subset regulators except Th22 regulators; (4) Vascular cells function as innate immune cells [as we reported previously for endothelial cells (52)], therefore, express numerous Th subsets-promoting cytokines and promote Th regulator expression other than Treg regulator expression; (5) GATA3 and Hdad6 promote, but Bcl6 inhibits, Th1 subset regulator expression in Treg by regulating Treg plasticity and heterogeneity; and (6) Furthermore, our results indicated that HDAC6 promotes but GATA3 and Bcl6 inhibit the expression of MHC class II molecules T cell co-signaling receptors expression in T-reg and “trans-differentiate” Treg into APC-like Treg. Therefore, based on our findings, we conclude that increased HDAC6 activity and reduced Bcl6 expression regulate the plasticity and heterogeneity of T-reg, but Gata3 expression level is the main determinant of Treg differentiation in to either Th1-Treg or APC-Treg.

It has been a common practice to perform microarray analysis and look for large fold changes (>2-folds) in gene expression with the treatment of interest. However, a recent report showed that in searching for the mechanism underlying NZW mouse Treg instability, gene expression profiles highlight specific
Deficiency of FOXP3 leads to failed development of Tregs, the biogenesis and immunosuppressive function of Tregs (significant if the translation factors such as Treg-associated FOXP3, can be functionally upregulated expression of MHC class II molecules and T cell co-stimulators in Treg. This transformation of Treg to APC-Treg deliver T cell activation signal 1 via MHC class II/antigen epitope complex and T cell activation signal 2 via co-stimulation receptors LIGHT, 4-1BBL, CD48, B7-1 (CD80) and CD112. This may potentially promote inflammation and immune responses.

**FIGURE 6** | A novel hypothesis. Functional interaction between Treg-specific transcription factor Foxp3 and other transcription factors and/or master genes such as Gata3, Bcl6 and Hdac6 to maintain Treg identity and prevent Treg from losing the immune-suppressing activity and the conversion to APC-like Treg. Bcl6 deficiency upregulate expression of MHC class II molecules and T cell co-stimulators in Treg. This transformation of Treg to APC-Treg deliver T cell activation signal 1 via MHC class II/antigen epitope complex and T cell activation signal 2 via co-stimulation receptors LIGHT, 4-1BBL, CD48, B7-1 (CD80) and CD112. This may potentially promote inflammation and immune responses.

---

differences in the transcriptome of NZW Tregs compared with those of other strains, but no single defect could obviously account for the Foxp3 instability. Rather, NZW Tregs show a general upregulation of transcripts normally repressed in Treg cells, which suggest that this network-level bias may account for NZW Treg instability (76). Along the same line, an innovative concept was presented and claimed that gene regulatory networks are sufficiently interconnected as such that all genes expressed in disease-relevant cells are liable to affect the functions of core disease-related genes. In addition, it was stated that most heritability can be explained by effects on genes outside the core pathways. Our findings support this new concept in the following ways: low levels of expression changes (<2.0-folds) of a group of functional related master genes, especially transcription factors such as Treg-associated FOXP3, can be functionally significant if the p values of gene expression are statistically significant (< 0.05). FOXP3 is a transcription factor in determining the biogenesis and immunosuppressive function of Tregs (1, 3). Deficiency of FOXP3 leads to failed development of Tregs (1); and the levels of FOXP3 in Tregs reflect their functional status (77).

We used an experimental database mining approach that was pioneered and developed in our laboratory throughout the years (7, 32, 75, 78). By analyzing sequencing data from tissue cDNA libraries, we were able to study expression profiles of Th subset regulators in various tissues. Since this data is collected from cDNA cloning and DNA sequencing experiments rather than theoretical data derived from computer modeling, the findings presented in this paper are more relevant to the biological systems. Since the gene expressed sequence tag (EST) data deposited in the NIH-NCBI-UniGene database have been established based on DNA sequencing data, the data obtained by EST database mining are more precise in providing the tissue expression profiles of genes than traditional hybridization- and primer annealing-based approaches like Northern blots and RT-PCRs (32). Of note, since the UniGene database does not have many non-tumor cell line-related gene expression data in various gene deficiencies and stimulation conditions, we analyzed microarray-based gene expression data deposited in NIH-GEO Datasets to determine Th subset regulator expression changes under pathological conditions. Nevertheless, we acknowledge that further experiments such as qPCR, flowcytometry, immunoblots etc. are required to verify the tissue expression profile patterns of Th subset regulators and microarray results we report here.

Recent progress demonstrated that in addition to inhibition of adaptive immune response, Treg also play a critical role in controlling various innate immune responses involved in cancers (2), inflammatory diseases including cardiovascular diseases and atherosclerosis (3), facilitate blood flow recovery after ischemia (4), control adipose tissue inflammation, and promote muscle repair (5). Herein, we report significant innovative findings, which allow us to propose a new working model (Figure 6): first, not only Treg have non-immune activities but also other Th subset may have this type of non-immune activities in various human tissues. Th subset regulators are not only expressed in secondary lymphoid tissues but also expressed in most other tissues, which may modulate Th subset tissue functions in a complex manner; second, as shown in our new Treg stability/plasticity model in Figure 7, Treg plasticity is not only toward Th1-Treg (26) and Th17-Treg (27) with the potential markers of GATA3/HDAC6/BCL6/FOXP3+, but also Treg plasticity upregulate MHC class II molecules and T cell co-stimulation receptors to function as antigen-presenting cells (APC-Treg with the potential markers of GATA3/HDAC6/BCL6/FOXP3+). Therefore, as mentioned above, our results demonstrated that while HDAC6 and Bcl6 are crucial to regulate Tregplasticity,
Fig. 7 | Newly proposed Treg stability/plasticity model: In order to maintain Treg stability, Treg need to express high level of FOXP3, HDAC6 and low levels of BCL6. GATA3 levels determine whether plastic T-reg will diverge into Th1-Treg or APC-Treg lineage. When GATA3 expression is diminished in the presence of high HDAC6 and low BCL6 levels, plastic T-reg tend to convert into APC-Treg. However, when GATA3 expression is increased with high levels of HDAC6 and low BCL6, T-reg convert into Th1-Treg. Increased plasticity of T-reg weakens its immunosuppressive function and may facilitate inflammation and autoimmune reactions.

Gata3 level in Treg determines whether the Treg is going to differentiate into either Th1-Treg or APC-Treg in the presence of increased HDAC and low Bcl6 expression. Although atypical APC activity was reported previously (69), the deficiencies of GATA3 and BCL6 in Treg leading to upregulation of MHC class II molecules and T cell co-stimulation receptors has not been reported before. This suggests that BCL6 and specifically GATA3 inhibit Treg converting itself to atypical APC. Of note, previous reports showed that FOXP3 can be presented by MHC class I and activate CD8+ anti-Treg (29, 30); and Treg-associated transcription factor FOXO3-upregulated tolerogenic dendritic cells express MHC class II and co-stimulation receptors (29, 30). Additionally, it was previously reported that expression of Bcl6 and IRF4 are required to specifically reduce subset-specific regulation of Th1 and Th17 cells, respectively. This report substantiates our findings that stability and maintenance of Bcl6
can be crucial to maintain Treg plasticity (79). Additionally, histone modifications were shown to regulate the Treg signature as well. It was shown that decreased abundance of H3K4Me3 downregulated the Treg signature genes while increased abundance of methylation at this specific site was observed in Th2-associated genes (80). To the best of knowledge, ours is the first report that claim acetylation of histone may also play a role in regulating the plasticity of T-reg. Our results have demonstrated for the first time that FOXP3 + Treg show plasticity and can convert into APC-Treg depending on the GATA3 expression level, therefore GATA3 is an important determinant of the fate of plastic Treg (Figure 7); third, a previous report showed that inducible Treg and Th17 cells, are more plastic than previously appreciated (81). However, our new findings demonstrated that inducible Treg express higher levels of Th1 cytokine IFNγ than natural Treg, suggesting that they have higher probability than natural Treg to be converted to Th1-Treg; and fourth, burn injury downregulates all the Th subset except Th22, indicating that Th22 is essential for tissue regeneration and repair. As we pointed out previously, data mining papers enable to generate new hypotheses and future experimental work is needed to consolidate our new findings. Nevertheless, our findings provide novel insights into Th subsets and Treg, which will eventually lead to future development of novel therapeutics for the treatment of inflammation, cancers, transplantation, autoimmune diseases and tissue regeneration.

REFERENCES

1. Yang WY, Shao Y, Lopez-Pastrana J, Mai J, Wang H, Yang XF. Pathological conditions re-shape physiological Tregs into pathological Tregs. Burns Trauma (2015) 3:1. doi:10.1186/s41038-015-0001-0
2. Ke X, Wang J, Li L, Chen H, Wang H, Yang XF. Roles of CD4+CD25(high) FOXP3+ Tregs in lymphomas and tumors are complex. Front Biosci (2008) 13:3986–4001.
3. Pastrana JL, ShaX, Virtue A, Mai J, Caeto R, Lee IA, et al. Regulatory T cells and atherosclerosis. J Clin Exp Cardiol (2012) 2012(Suppl 12):2. doi:10.4172/2155-9880:S12-002
4. Shariat R, Semo J, Shaish A, Landa-Rouben N, Entin-Meer M, Keren G, et al. Regulatory T cells influence blood flow recovery in experimental hindlimb ischaemia in an IL-10-dependent manner. Cardiovasc Res (2014) 103(4):585–96. doi:10.1093/cvr/cvu159
5. Burzyn D, Benoist C, Mathis D. Regulatory T cells in nonlymphoid tissues. Nat Immunol (2013) 14(10):1007–13. doi:10.1038/ni.2683
6. Shao Y, Cheng Z, Li X, Chernyayev V, Wang H, Yang XF. Immunosuppressive/anti-inflammatory cytokines directly and indirectly inhibit endothelial dysfunction – a novel mechanism for maintaining vascular function. J Hematol Oncol (2014) 7:80. doi:10.1186/s13045-014-0088-6
7. Li X, Mai J, Virtue A, Yin Y, Gong R, Sha X, et al. IL-35 is a novel responsive anti-inflammatory cytokine – a new system of categorizing anti-inflammatory cytokines. PLoS One (2012) 7(3):e33628. doi:10.1371/journal.pone.0033628
8. Sha X, Meng S, Li X, Xi H, Maddaloni M, Pascual DW, et al. Interleukin-35 inhibits endothelial cell activation by suppressing MAPK-AP-1 pathway. J Biol Chem (2015) 290(31):19307–18. doi:10.1074/jbc.M115.663286
9. Li X, Fang P, Yang WT, Shi H, Yang X. IL-35, as a newly proposed homeostasis-associated molecular pattern, plays three major functions including anti-inflammatory initiator, effector, and blocker in cardiovascular diseases. Cytokine (2017). doi:10.1016/j.cyto.2017.06.003
10. Brach N, Yang XF, Crine P, Cohen P, Boileau G. Predominant basolateral proteolytic processing of prostatostatin into somatostatin-28 in polarized LLC-PK1 cells. Neuropeptides (1997) 31(5):393–8. doi:10.1016/S0143-4179(97)90030-5
11. Yang Y, Yang F, Xiong Z, Yan Y, Wang X, Nishino M, et al. An N-terminal region of translationally controlled tumor protein is required for its antiapoptotic activity. Oncogene (2005) 24(30):4778–88. doi:10.1038/sj.onc.1208666
12. Xiong Z, Song J, Yan Y, Huang Y, Cowan A, Wang H, et al. Higher expression of Bax in regulatory T cells increases vascular inflammation. Front Biosci (2008) 13:7143–55. doi:10.2741/3217
13. Xiong Z, Yan Y, Song J, Fang P, Yin Y, Yang Y, et al. Expression of TCTP antisense in CD25(high) regulatory T cells aggravates cuff-injured vascular inflammation. Atherosclerosis (2009) 203(2):401–8. doi:10.1016/j.atherosclerosis.2008.07.041
14. Yang XF. Factors regulating apoptosis and homeostasis of CD4+ CD25(high) FOXP3+ regulatory T cells are new therapeutic targets. Front Biosci (Schol Ed) (2009) 14:20–36. doi:10.2741/s35
15. Yang XF, Fang P, Meng S, Jan M, Xiong X, Yin Y, et al. The FOX transcription factors regulate vascular pathology, diabetes and Tregs. Front Biosci (Schol Ed) (2009) 203(2):401–8. doi:10.1016/j.atherosclerosis.2008.07.041
16. Xiong Z, Yin Y, Wang H. Vascular inflammation and atherogenesis are activated via receptors for pamps and suppressed by regulatory T cells. Drug Disc Today Ther Strateg (2008) 5(2):125–42. doi:10.1016/j.ddstr.2008.11.003
17. Yang Y, Yin Y, Wang H. Vascular inflammation and atherogenesis are activated via receptors for pamps and suppressed by regulatory T cells. Drug Disc Today Ther Strateg (2008) 5(2):125–42. doi:10.1016/j.ddstr.2008.11.003
18. Yan Y, Xiong Z, Zhang S, Song J, Huang Y, Thornton AM, et al. CD25high T cells with a prolonged survival inhibit development of diabetes. Int J Immunopathol Pharmacol (2008) 21(4):767–80. doi:10.1177/039463200802100401
19. Lopez-Pastrana J, Shao Y, Chernyayev V, Wang H, Yang XF. Epigenetic enzymes are the therapeutic targets for CD4(+)/CD25(high)/Foxp3(+) regulatory T cells. Transl Res (2015) 165(1):221–8. doi:10.1016/j.trsl.2014.08.001
20. Shao Y, Chernyayev V, Johnson C, Yang WY, Curiel R, Sha X, et al. Metabolic diseases downregulate the majority of histone modification enzymes, making a few upregulated enzymes novel therapeutic targets-“sand out and gold stays”. J Cardiovasc Transl Res (2016) 9(1):49–66. doi:10.1007/s12265-015-9664-y
21. Webb LMC, Linterman MA. Signals that drive T follicular helper cell formation. Immunology (2017) 152(2):185–94. doi:10.1111/imm.12778

AUTHOR CONTRIBUTIONS

KX carried out the data gathering, data analysis, figures/tables preparation, and manuscript writing. Other authors provided material input and helped revising the manuscript. XY supervised the experimental design, data analysis. All authors read and approved the final manuscript.

FUNDING

This work was supported by NIH grant to Dr. XF. Yang (Grant No. RO1-HL132399-01A1).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at http://www.frontiersin.org/articles/10.3389/fimmu.2018.00045/full#supplementary-material.

FIGURE S1 | Th subset regulator mRNA transcripts are differentially expressed in healthy human tissues.

FIGURE S2 | Th transcription factor (TF) Bcl6 and Th2-TF Gata3 inhibit, but Hdac6 promotes Treg to become APC-like Treg. We conducted an Ingenuity Pathway Analysis to determine the signaling pathways that are regulated by the genes that are modulated by theses TF. The Venn diagram analysis showed that the majority of signaling pathways that are modulated by genes that are upregulated due to Gata3 deficiency and by the genes that are downregulated by Hdac6 deficiency are shared.
A genomic storm in critically injured humans. *Curr Opin Allergy Clin Immunol* (2015) 15(1):41–8. doi:10.1097/AOI.0000000000000129

Takeuchi A, Saito T. CD4 CTL, a cytotoxic subset of CD4+ T cells, their differentiation and function. *Front Immunol* (2017) 8:1944. doi:10.3389/fimmu.2017.00194

Katz A, Domínguez-Villar M. Molecular mechanisms underlying Th1-like Treg generation and function. *Cell Mol Life Sci* (2017) 74(22):4059–75. doi:10.1007/s00018-017-2569-y

Butcher MJ, Filopisarz AW, Waseem TC, McGary CM, Crow KJ, Maglnick N, et al. Atherosclerosis-driven Treg plasticity results in formation of a dysfunctional subset of plastic IFNγ+ Th1/Tregs. *Circ Res* (2016) 119(11):1190–203. doi:10.1161/CIRCRESAHA.161.309764

Pandiyi P, Zhu J. Origin and functions of pro-inflammatory cytokine produced Foxp3+ regulatory T cells. *Cytokine* (2015) 76(1):13–24. doi:10.1016/j.cyto.2015.07.005

Sharir R, Semo J, Shimmion S, Ben-Mordechai T, Landau-Rouben N, Maysel-Auslander S, et al. Experimental myocardial infarction induces altered regulatory T cell hemostasis, and adoptive transfer attenuates subsequent remodeling. *PLoS One* (2014) 9(12):e113653. doi:10.1371/journal.pone.0113653

Anderson ML. Anti-inflammatory T cells. *Semin Immunopathol* (2017) 39(3):317–26. doi:10.1007/s00281-016-0593-x

Larsen SK. Cellular immune responses towards regulatory cells. *Dan Med J* (2016) 63(188).

Levine AG, Mosdro A, Himmens S, Molbedo B, Niec RE, Schizas M, et al. Stability and function of regulatory T cells expressing the transcription factor T-bet. *Nature* (2017) 547(7658):421–5. doi:10.1038/nature22360

Yin Y, Yan Y, Jiang X, Mai J, Chen NC, Wang H, et al. Inflammasones are differentially expressed in cardiovascular and other tissues. *Int J Immunopathol Pharmacol* (2009) 22(2):311–22. doi:10.1177/0394632009022002008

Hardy OT, Perugini RA, Nicoloro SM, Gallagher-Dorval K, Purv V, Straubhaar J, et al. Body mass index-independent inflammation in onmental adipose tissue associated with insulin resistance in morbid obesity. *Surg Obes Relat Dis* (2011) 7(1):60–7. doi:10.1016/j.soard.2010.05.013

Kirchner H, Sinha I, Gao H, Ruby MA, Schonke M, Lindvall JM, et al. Altered DNA methylation of glycolytic and lipogenic genes in liver from obese and type 2 diabetic patients. *Metabol* (2016) 5(3):171–83. doi:10.1016/j.molmet.2015.12.004

Abd Alla J, Graemer M, Fu X, Quitterer U. Inhibition of G-protein-coupled receptor kinase 2 prevents the dysfunctional cardiac substrate metabolism in fatty acid synthase transgenic mice. *J Biol Chem* (2016) 291(6):2583–600. doi:10.1074/jbc.M115.702688

Yin C, Mohanta S, Ma Z, Weber C, Hu D, Weih E, et al. Generation of aorta transcript atlases of wild-type and apolipoprotein E-null mice by laser capture microdissection-based mRNA expression microarrays. *Methods Mol Biol* (2015) 1339:297–308. doi:10.1007/978-1-4939-2929-2_10

Mosig S, Rennert K, Butttner P, Krause S, Liu J, Soufi M, et al. Monocytes in fatty acid synthase transgenic mice. *Arterioscler Thromb Vasc Biol* (2010) 30(3):395–402. doi:10.1161/ATVBAHA.110.193195

Bhaumik S, Basu R. Cellular and molecular dynamics of Th17 differentiation and its developmental plasticity in the intestinal immune response. *Front Immunol* (2017) 8:254. doi:10.3389/fimmu.2017.00254

Mai J, Virtue A, Shen J, Wang H, Yang XF. An evolving new paradigm: endothelial cells – conditional innate immune cells. *J Hematol Oncol* (2013) 6:61. doi:10.1186/1756-8722-6-61

Yin Y, Li X, Sha X, Xi H, Li YF, Shao Y, et al. Early hyperlipidemia promotes endothelial activation via a caspase-1-sirtuin 1 pathway. *Arterioscler Thromb Vasc Biol* (2015) 35(4):804–16. doi:10.1161/ATVBAHA.115.305282

Lotzer K, Dopping S, Connert S, Grabner R, Spanbroek R, Lemser B, et al. Mouse aorta smooth muscle cells differentiate into lymphoid tissue organizer-like cells on combined tumor necrosis factor receptor-1/lymphotixin beta-receptor NK-κappaB signaling. *Arterioscler Thromb Vasc Biol* (2010) 30(3):395–402. doi:10.1161/ATVBAHA.109.193195

Piconese S, Barnaba V. Stability of regulatory T cells undermined or endorsed by different type 1 cytokines. *Adv Exp Med Biol* (2015) 850:17–30. doi:10.1007/978-3-319-15774-0_2

McClymont SA, Putnam AL, Lee MR, Eseten JH, Liu W, Hulme MA, et al. Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. *J Immunol* (2011) 187(7):3918–26. doi:10.4049/jimmunol.1003099

Komatsu N, Okamoto K, Sawa S, Nakashima T, Oh-hora M, Kodama T, et al. Pathogenic conversion of Foxp3+ T cells into Th17 cells in autoimmune arthritis. *Nat Med* (2014) 20(1):62–8. doi:10.1038/nm.3432

Schmitt EG, Haribhai D, Williams JB, Aggarwal P, Jia S, Charbonnier LM, et al. Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. *J Immunol* (2011) 187(7):3918–26. doi:10.4049/jimmunol.1003099

Corse E, Allison JP. Cutting edge: CTLA-4 on effector T cells inhibits in trans. *J Immunol* (2013) 183(6):3731–41. doi:10.4049/jimmunol.0800601

Fu W, Ergun A, Lu T, Hill JA, Haxhinasto S, Sessett MS, et al. A multiply redundant genetic switch ‘locks in’ the transcriptional signature of regulatory T cells. *Nat Immunol* (2012) 13(10):972–80. doi:10.1038/ni.2420

Zhou X, Jehes UT, Fife BT, Zhu S, Anderson MS, McManus MT, et al. Selective microRNA disruption in T reg cells leads to uncontrolled autoimmune. *J Exp Med* (2008) 205(9):1983–91. doi:10.1084/jem.20080707

Corse E, Allison JP. Cutting edge: CTLA-4 on effector T cells inhibits in trans. *J Immunol* (2012) 189(3):1123–7. doi:10.4049/jimmunol.1200695
Transcription Factors and Treg Plasticity

Xu et al.

Copyright © 2018 Xu, Yang, Nanayakkara, Shao, Yang, Hu, Choi, and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited with a link to the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.